Value-Based Indication-Specific Pricing and Weighted-Average Pricing: Estimated Price and Cost Savings for Cancer Drugs
PharmacoEconomics · 2025-04 · 43 (4) · 415-427
DOI: 10.1007/s40273-024-01448-x ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift PharmacoEconomics, online erschienen am 30.12.2024. Verfasst von Daniel Tobias Michaeli und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Im Neuenheimer Feld 460, 69120, Heidelberg, Germa…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Cost Savings, Drug Costs, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Universitätsklinikum Heidelberg.
Abstract (Originalsprache)
OBJECTIVES: For US Medicare and Medicaid, single drug prices do not reflect the value of supplemental indications. Value-based indication-specific and weighted-average pricing has been suggested for drugs with multiple indications. Under indication-specific pricing, a distinct price is assigned to the differential value a drug offers in each indication. Under weighted-average pricing, a single drug price is calculated that reflects the value and/or volume of each indication. This study estimates price reductions and cost savings for cancer drugs under value-based indication-specific pricing and weighted-average pricing. METHODS: We collected data on US Food and Drug Administration (FDA)-approved cancer drugs and indications (2003-2020) from FDA labels, the Global Burden of Disease study, clinicaltrials.gov, and Medicare and Medicaid. A multivariable regression analysis, informed by characteristics of original indications, was used to predict value-based indication-specific prices for supplemental indications. These indication-specific prices were combined with each indication's prevalence data to estimate value-based weighted-average prices and potential cost savings under each policy. RESULTS: We identified 123 cancer drugs with 308 indications. Medicare and Medicaid spent a total of $28.2 billion on these drugs in 2020. Adopting value-based indication-specific pricing would increase drug prices by an average of 3.9%, with cost savings of $3.0 billion (10.6%). However, 43.7% higher prices for ultra-rare diseases would increase spending by 16.8% ($44 million). Adopting value-based weighted-average pricing would reduce prices by an average of 4.6% and spending by $3.0 billion (10.6%). Under weighted-average pricing, prices for and spending on ultra-rare diseases would be reduced by 22.6% and $55 million, respectively. CONCLUSIONS: Value-based indication-specific and weighted-average pricing could help to align the value and price of new indications, thereby reducing expenditure on drugs with multiple indications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Im Neuenheimer Feld 460, 69120, Heidelberg, Germany. danielmichaeli@yahoo.com.
- Schumpeter School of Business and Economics, University of Wuppertal, Wuppertal, Germany. danielmichaeli@yahoo.com.
- Schumpeter School of Business and Economics, University of Wuppertal, Wuppertal, Germany.
- Department of Personalized Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
- DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany.
- Division of Personalized Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
ORCID-Profile: Daniel Tobias Michaeli, Thomas Michaeli
Förderung
- Universitätsklinikum Heidelberg
Zitieren
APA
Michaeli, D. T., & Michaeli, T. (2025). Value-Based Indication-Specific Pricing and Weighted-Average Pricing: Estimated Price and Cost Savings for Cancer Drugs. PharmacoEconomics, 43(4), 415-427. https://doi.org/10.1007/s40273-024-01448-x
Vancouver
Michaeli DT, Michaeli T. Value-Based Indication-Specific Pricing and Weighted-Average Pricing: Estimated Price and Cost Savings for Cancer Drugs. PharmacoEconomics. 2025;43(4):415-427. doi:10.1007/s40273-024-01448-x
BibTeX
@article{Michaeli2025,
author = {Michaeli, Daniel Tobias and Michaeli, Thomas},
title = {Value-Based Indication-Specific Pricing and Weighted-Average Pricing: Estimated Price and Cost Savings for Cancer Drugs},
journal = {PharmacoEconomics},
year = {2025},
volume = {43},
number = {4},
pages = {415--427},
doi = {10.1007/s40273-024-01448-x}
}
EUVIMED